Date: 2012-06-18

Type of information: R&D agreement

Compound: kinetic biomarkers

Company: KineMed (USA) GSK (UK)

Therapeutic area: Metabolic diseases - Neuromuscular diseases

Type agreement:


Action mechanism:

Disease: muscle wasting, fibrosis, metabolic diseases


KineMed, a californian biomarker discovery and development company, and GSK have concluded a multi-year R&D collaboration agreemeent to develop kinetic biomarkers. KineMed will apply its proprietary biomarker discovery platform and their collaboration will seek to identify, optimize and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.

Financial terms:

Financial terms were not disclosed.

Latest news:

Is general: Yes